Medtronic, Inc. – FDA Warning Letter, Jul 7, 2021

On December 9, 2021, the FDA issued a Warning Letter to Medtronic, Inc. following a June-July 2021 inspection of their Northridge, California facility. The inspection revealed that Medtronic's MiniMed 600 series insulin infusion pumps and associated software/remote controllers were adulterated under 21 U.S.C. § 351(h) due to non-conformity with Quality System regulation (21 CFR Part 820).

Key violations include: 1. **Inadequate Corrective and Preventive Action (CAPA) Procedures (21 CFR 820.100(a)):** * Failure to adequately address increased complaints of damaged clear retainer rings in MiniMed 600 series pumps (CAPA #299677). Medtronic's risk calculation underestimated the probability of harm, leading to a delayed Class I recall (RES84430) until November 2019, despite over 74,000 complaints. * Failure to adequately verify/validate the effectiveness of the redesigned black retainer ring, as 322 complaints were received for the new design during the effectiveness check period, and 53,000 total complaints for the black retainer ring as of May 2021. * Inadequate response to a cybersecurity vulnerability in remote